ANTI-IgE gene therapy
OwnerRuey S. Liou, David Thomasinventors
Life of this patent
Estimating the term…
Abstract
Disclosed are gene constructs of anti-IgE antibodies or fragments thereof for therapy for allergic diseases. Upon introduction into suitable host, anti-IgE antibody gene constructs will direct the synthesis of an antibody (or its fragments) capable of binding to free IgE in serum but not binding to IgE bound to the high affinity receptor (FcεRI), or not binding to IgE bound to both the high affinity receptor and the low affinity receptor (FcεRII or CD23). The antibody (or fragments) which are synthesized may also inhibit IgE binding to the high affinity receptor or the low affinity receptor, or to both.
Claims16
A method of expressing an anti-IgE antibody, or a functional variant or fragment thereof, which does not bind to IgE bound to FcεRI, in a host cell comprising introducing an expression vector encoding the anti-IgE antibody, or functional variant or fragment thereof, into a host cell and maintaining the expression in the cell.
A method of inducing a host cell to express an anti-IgE antibody, or a functional variant or fragment thereof, comprising administering an expression vector encoding an anti-IgE antibody, or a functional variant or fragment thereof.
A method of expressing in a host cell an anti-IgE antibody, or a functional variant or fragment thereof, comprising administering a formualtion comprising a nucleic acid sequence encoding an anti-IgE antibody or a functional variant or fragment thereof, which does not bind to IgE bound to FcεRI.
A method of treating an IgE-mediated allergic disease comprising administering a formulation comprising an expression vector encoding an anti-IgE antibody, or functional variant or fragment thereof, which does not bind to IgE bound to FcεRI.
Dependencies are inferred from the claim text.